for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Histogen Inc

HSTO.OQ

Latest Trade

0.21USD

Change

-0.01(-6.33%)

Volume

118,369

Today's Range

0.21

 - 

0.24

52 Week Range

0.21

 - 

1.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.22
Open
0.24
Volume
118,369
3M AVG Volume
15.02
Today's High
0.24
Today's Low
0.21
52 Week High
1.98
52 Week Low
0.21
Shares Out (MIL)
49.95
Market Cap (MIL)
11.84
Forward P/E
-0.56
Dividend (Yield %)
--

Next Event

Q4 2021 Histogen Inc Earnings Release

Latest Developments

More

Histogen Reports Qtrly Loss Per Share Of 9 Cents

Histogen Posts Quarterly Loss Per Share Of $0.10

Histogen And Amerimmune Announce Positive Top-Line Study Results From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Histogen Inc

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. It has a portfolio of product candidates derived from one core technology process that utilizes proteins and growth factors produced by hypoxia-induced multipotent cells, without using embryonic stem cells or animal components. The Company's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. HST 003 is a human extracellular matrix (hECM), a naturally secreted material, which is used for treatment of joint cartilage repair. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being jointly developed with its partner Amerimmune for the treatment of COVID-19.

Industry

Biotechnology & Drugs

Contact Info

10655 SORRENTO VALLEY ROAD, SUITE 200

SAN DIEGO, CA

92121

United States

+1.858.5263100

https://histogen.com/

Executive Leadership

Steven J. Mento

Executive Chairman of the Board, Interim President, Interim Chief Executive Officer

Gail Naughton

Founder, Chief Scientific Officer, Chief Business Development Officer

Susan A. Knudson

Chief Financial Officer, Executive Vice President, Corporate Secretary

Moya Daniels

Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Martin Latterich

Senior Vice President - Technical Operations

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-5.900

2019

-3.400

2020

-2.080

2021(E)

-0.425
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.87
Price To Book (MRQ)
0.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.04
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-78.78
Return on Equity (TTM)
-74.09

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up